My wife is 58 with NSCLC and ALK+. She was on Crizotinib but progressed after about 13 months. She recently joined 2nd gen trial with ASP3026 with Dr. Gandara at UC Davis and seems to be having a positive response after first cycle. Looking ahead, have you heard of any work being done on 3rd gen ALK+ inhibitors or is it just too early (not enough experience with patients who have progressed on 2nd gen to guide development of 3rd gen)? Are there significant enough differences in the 2nd gen drugs that would suggest being able to migrate to a different 2nd gen drug after progression or are you limited to only one 2nd gen drug with little expected benefit from different 2nd gen drugs?
Sun, 07/14/2013 - 08:23#1
3rd Generation ALK Inhibitors? - 1257908